InvestSMART

Noxopharm Limited (ASX:NOX)

ALERT: Price-sensitive ASX Announcement for NOX
Current share price for NOX : $0.049 -0.035 (-41.67%)+
Announcement
Release
28 Aug 2026 4:34PM
Price at Release
$0.084
Full Release
download
Summary
Noxopharm Limited’s Appendix 4E Preliminary Financial Report for the Australian financial year ended 30 June 2026, released on 28 August 2026, reports an unaudited consolidated loss after tax of $4,455,877, an 8.8% improvement on the prior year’s $4,884,170 loss, with no dividends declared and net tangible assets per ordinary security falling to negative 0.01 cents from 0.24 cents. The company’s principal activity during FY2026 was SOF-SKN clinical trial preparation and broader drug development focused on inflammation, autoimmune disease, cancer and mRNA vaccine improvement, with operational highlights including successful completion of the first-in-human HERACLES trial for SOF-SKN, publication of Sofra platform science in Nature Immunology, encouraging autoimmune and cancer-related preclinical data, additional material transfer agreements, manufacturing commencement for a future clinical trial, and a $5 million At-the-Market Subscription Agreement with Acuity Capital. Financially, income declined to $1.45 million mainly from R&D tax incentives, research and development expenses reduced materially to $1.94 million, consulting, employee and director expenses were $2.10 million, finance costs increased to $1.16 million, cash and cash equivalents fell to $293,573 from $1.55 million, and the group moved to a net liability position of $3.65 million from net assets of $689,963, driven largely by $4.37 million in convertible notes and a $200,592 unsecured related-party loan; the report also notes extension and modification of convertible note terms, derivative liability valuation impacts, an extended licence agreement with milestone and royalty obligations, and that no significant events occurred after 30 June 2026.
Key Points
  • Appendix 4E preliminary final report covers the year ended 30 June 2026 for Noxopharm Limited.
  • Announcement date is 28 August 2026 and the report is unaudited.
  • Loss after tax attributable to owners was $4,455,877, down 8.8% from $4,884,170 in FY2025.
  • No dividends were paid, recommended or declared for FY2026.
  • Net tangible assets per ordinary security were negative 0.01 cents, compared with 0.24 cents in the prior year.
  • Principal activity was SOF-SKN clinical trial preparation and drug development focused on inflammation, autoimmune diseases, cancer and mRNA vaccines.
  • Noxopharm reported successful completion of the HERACLES first-in-human SOF-SKN trial with no relevant safety issues across four concentrations.
  • The company highlighted publication of Sofra platform science in Nature Immunology.
  • New data indicated anti-inflammatory activity of the SOF-SKN active ingredient in patient samples from systemic lupus erythematosus and rheumatoid arthritis studies.
  • Noxopharm reported progress in using the Sofra platform for cancer through TLR8-targeting oligonucleotides.
  • The company signed further material transfer agreements for external evaluation of Sofra platform assets.
  • Dr Olivier Laczka was appointed CEO during the year.
  • Tezcat Biosciences reported promising preclinical results using Sofra assets with its delivery system.
  • Noxopharm strengthened its partnership with Hudson Institute of Medical Research.
  • The company engaged a global CRO ahead of a pre-IND meeting with the US FDA and commenced SOF-SKN manufacturing for a future clinical trial.
  • An At-the-Market Subscription Agreement with Acuity Capital provides up to $5 million of standby equity capital to 31 July 2031.
  • Total income was $1,449,303, including $1,427,373 in R&D tax incentives and $21,930 in interest income.
  • Research and development expenses fell to $1,943,024 from $4,266,476.
  • Consulting, employee and director expenses were $2,102,692 and corporate administration expenses were $799,845.
  • Finance costs rose to $1,159,528, largely due to convertible note interest.
  • Cash and cash equivalents decreased to $293,573 from $1,554,174.
  • Trade and other receivables were $1,509,324, mainly comprising the R&D rebate receivable.
  • Total liabilities increased to $5,484,914 from $3,891,442.
  • Convertible notes payable totalled $4,372,861 at 30 June 2026.
  • Net assets moved to a deficiency of $3,647,914 from positive equity of $689,963 in FY2025.
  • The company disclosed a $200,592 unsecured related-party loan from 4F Investments Pty Limited at year end.
  • The licence agreement includes milestone and royalty obligations and was extended for a further 12 months during FY2026.
  • No significant matters arose after 30 June 2026, and the annual report was stated as unlikely to be subject to dispute or qualification.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.